Infectious Disease · Internal Medicine · 2 h ago
Pneumonia response criteria need explicit estimands in trials
This commentary argues that standardized hospital-acquired and ventilator-associated pneumonia response criteria do not alone define the treatment effect a randomized trial estimates. It highlights how handling deaths before assessment can change outcome classification and the interpretation of comparisons among survivors.
- Death handling can materially change pneumonia failure rates.
- Survivor-only comparisons may not preserve randomized causal contrasts.
- Authors recommend prespecifying trial estimands and intercurrent-event strategies.
The commentary examines a proposed framework for assessing treatment response in ventilated patients with hospital-acquired or ventilator-associated pneumonia (HAP/VAP). It argues that response criteria should be paired with an explicit estimand: the target population, treatment conditions, outcome, handling of death and other events that prevent outcome assessment, and treatment-effect measure.
In the cohort cited by the authors, 302 of 1,603 pneumonia episodes had an indeterminate overall outcome, including 240 because of death. Counting death as treatment failure increased the failure proportion from 22.2% to 34.3%. The authors caution that comparing only patients alive and classifiable at day 10 can undermine the randomized comparison if treatment affects survival. They describe composite outcomes and desirability-of-outcome ranking (DOOR) as possible approaches, while noting that survivor average causal effect analyses require assumptions beyond randomization.
The article is a commentary, not a new clinical trial or reanalysis. It says observed associations between response classification and later outcomes support prognostic discrimination among assessable patients, but do not establish that survivor-restricted treatment comparisons retain a causal interpretation. The authors recommend prespecifying the estimand without requiring a single strategy for handling death.
In practice
For investigators designing randomized trials of HAP/VAP treatments, standardized response criteria alone do not determine the treatment effect being estimated. Protocols should specify how death and other events that prevent assessment are handled, alongside the population, outcome and effect measure. In the cited cohort, counting death as failure raised the failure proportion from 22.2% to 34.3%. Comparisons restricted to day-10 survivors may not preserve randomization if treatment affects survival; this commentary does not establish a preferred strategy or support changing clinical care.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Critical Care: Standardizing pneumonia response does not by itself define the treatment estimand ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.